Skip to main content

Cross-sectional study to determine prevalence of significant liver fibrosis (F2–F4) in HIV/HCV co-infected patients: GRAFIHCO study

Purpose of the study

HIV/HCV co-infection is highly prevalent in Spain (50%–60%), and liver disease is the leading cause of morbidity and mortality among those individuals. Currently, liver biopsy is considered to be the gold standard for assessing significant liver fibrosis in the context of HCV-related liver disease. Multiple biopsies are impractical, costly, and could lead to infrequent but serious complications, however, non-invasive measures of liver fibrosis could therefore offer significant advantages. The objective of this cross-sectional study was to estimate the prevalence of significant liver fibrosis (SLF) in HIV/HCV patients in Spain using APRI and Forns index.

Methods

Patients are considered to have SLF if they have an APRI score >1.5 or an APRI score <1.5 but a Forns index score >6.9. Data from Fibroscan and biopsies were collected when available.

Summary of results

Results from 8,829 evaluable patients (78.3% male) have been analyzed. Mean age 41.8 ± 6.2 years; 91.6% on antiretroviral treatment (ARVT). 57.9% of the patients were infected by HCV genotype 1, 20.5% genotype 3, 16.1% genotype 4, 3.2% genotype 2, and 2.3% other genotypes. 30.6% of the patients were diagnosed of SLF according to the APRI/Forns algorithm. Nadir CD4 cell count was lower in patients with SLF than in those without SLF, median 159 cells/mcg vs. 191 cells/mcg, respectively (p < 0.001); OR (for each 100 cell increase) = 0.92 (95% CI: 0.89–0.95). SLF was also more prevalent among male than among female patients, 32.7% vs. 23.2%, respectively (p < 0.001); [OR 0.63 (95% CI: 0.56–0.71)]. Results from biopsy and Fibroscan were collected in 1,701 and 1,879 patients, respectively. 53.3% of the patients had F2–F4 according to biopsy and 56.1% according to Fibroscan (>7 kPa). The positive predictive value of the algorithm according to biopsy results for SLF was 79.2% (95% CI: 67.7–90.7).

Conclusion

An algorithm of biomarkers, including APRI and Forns index, identifies a significant proportion of HIV/HCV co-infected patients with F2–F4 liver fibrosis in daily clinical practice, although its performance is slightly lower than that reported in prior validation studies. Immunodepression and male sex are the main factors associated with significant fibrosis assessed by this procedure.

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Reprints and Permissions

About this article

Cite this article

Tural, C., Ortega, E., Pineda, J. et al. Cross-sectional study to determine prevalence of significant liver fibrosis (F2–F4) in HIV/HCV co-infected patients: GRAFIHCO study. JIAS 11, P264 (2008). https://doi.org/10.1186/1758-2652-11-S1-P264

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-11-S1-P264

Keywords

  • Liver Disease
  • Liver Fibrosis
  • Daily Clinical Practice
  • Significant Fibrosis
  • Multiple Biopsy